Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times

Big Pharma won't let the vaccine out

Big Pharma won't let the vaccine out

Waiving Covid vaccine patents would help poor countries fight the disease. Pharma giants won't let that happen

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters

Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Marjorie Taylor Greene condemns Covid boosters by claiming polio vaccine is only one jab – but it actually takes four

‘I think the question we all should ask is “when does it stop?” and “when are enough vaccines enough?”’ Greene said

The Independent UK

Moderna Surges After Asking FDA To Sign Off On Another Covid Booster

Moderna asked the FDA to authorize its Covid booster for all adults — a much wider request than Pfizer's — and Moderna stock popped Friday.

Investors Business Daily

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Moderna Seeks US Approval of Second Covid Booster

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's Covid-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 vaccine in adults 18…

Asharq Al-Awsat

inkl

Read news from The Economist, FT, and more,
with one subscription

Moderna requests FDA approval for fourth COVID shot for adults

Moderna Inc. has filed for U.S. regulatory clearance of a second COVID-19 booster shot for all adults, covering significantly more people than Pfizer Inc. and BioNTech SE’s request earlier this week for a more limited emergency authorization for those over 65.

Tribune News Service

Moderna asks FDA to authorize additional booster shot for all adults

Moderna asks FDA to authorize additional booster shot for all adults

The request is much broader than Pfizer's, which sought to authorize a second booster for people over 65.

Vic strikes mRNA vaccine deal with Pfizer

Vic strikes mRNA vaccine deal with Pfizer

Drug company Pfizer has agreed to increase collaboration with Victorian researchers working on mRNA vaccines.

Anti-vaxxers are claiming an outbreak of Japanese encephalitis is really being caused by adverse reactions to Pfizer's vaccine. Here's why that's bunkum

Anti-vaxxers are claiming an outbreak of Japanese encephalitis is really being caused by adverse reactions to Pfizer's vaccine. Here's why that's bunkum

Anti-vaxxers are once again using a Pfizer document to spread misinformation, this week claiming that Japanese encephalitis is a cover-up for adverse reactions to the company's vaccine.

19 firms in India to make Pfizer’s oral COVID-19 antiviral drug

19 firms in India to make Pfizer’s oral COVID-19 antiviral drug

They have signed sublicence agreements with United Nations-backed Medicines Patent Pool

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill

Thirty-five generic drugmakers will produce low-cost versions of Pfizer Inc's (NYSE:PFE) COVID-19 pill, Paxlovid, to expand supplies of the highly effective drug in lower-income regions. Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries, covering up to approximately 53% of the…

More than 30 companies to start making Pfizer's COVID pill

More than 30 companies to start making Pfizer's COVID pill

The U.N.-backed Medicines Patent Pool says that nearly three dozen companies worldwide will soon start making generic versions of Pfizer’s coronavirus pill

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

The Guardian - UK

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in…

Get all your
news in one place.

100’s of premium titles.
One news app.

COVID boosters' short effectiveness window brings skepticism about 4th shot

Some experts are already skeptical that another shot is warranted for most people.

Los Angeles Times

Second COVID-19 booster shot does little to stop omicron, study finds

Israeli health care workers who were boosted with a fourth shot of COVID-19 vaccine at the height of the omicron wave were only marginally more protected against reinfection than their peers who had received three jabs of vaccine, researchers reported Wednesday.

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Asharq Al-Awsat

Pfizer-BioNTech Seek US Approval of Second Covid Booster for 65+

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older. The companies said in a press statement that their request is based off two Israeli studies that show…

Tribune News Service

Pfizer asks FDA to clear another booster for older adults

Pfizer Inc. said it has asked U.S. regulators for clearance of an additional COVID-19 booster shot for seniors, in a bid to protect vulnerable adults as immunity provided by the first three doses wanes.

The Loop: Another Pfizer booster on table in US, hospital hostages in beseiged Mariupol, and a Grammys showstopper

Here's your TL;DR for this morning's news.

1 … 61 62 63 64

People

Marjorie Taylor Greene

Tanya Plibersek

Stéphane Bancel

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

250,003 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play